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Abstract
 Scope—Lipoprotein particle measures performed by nuclear magnetic resonance (NMR), and 
associated ratios, may be better markers for atherosclerosis risk than conventional lipid measures. 
The effect of two functional olive oils, one enriched with its polyphenols (FVOO, 500 ppm), and 
the other (FVOOT) with them (250 ppm) and those of thyme (250 ppm), versus an standard virgin 
olive oil (VOO), on lipoprotein particle atherogenic ratios and subclasses profiles was assessed.
 Methods and Results—In a randomized, double-blind, crossover, controlled trial, 33 
hypercholesterolemic individuals received 25 mL/day of VOO, FVOO, and FVOOT. Intervention 
periods were of 3-weeks separated by 2-week washout periods. Lipoprotein particle counts and 
subclasses were measured by NMR. Polyphenols from olive oil and thyme modified the 
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lipoprotein subclasses profile and decreased the total LDL particle/total HDL particle (HDL-P), 
small HDL/large HDL, and HDL-cholesterol/HDL-P ratios, and decreased the lipoprotein insulin 
resistance index (LP-IR) (P<0.05).
 Conclusions—Olive oil polyphenols, and those from thyme provided benefits on lipoprotein 
particle atherogenic ratios and subclasses profile distribution. Polyphenol-enriched olive oil is a 
way of increasing the olive oil healthy properties while consuming the same amount of fat, as well 
as a useful and complementary tool for the management of cardiovascular risk individuals.
Keywords
HDL-C/HDL-P and LDL-P/HDL-P ratios; lipoprotein subclasses; olive oil; polyphenols; thyme
 1. Introduction
In experimental and human studies, polyphenol-rich foods have shown to improve the lipid 
cardiovascular risk profile. Thyme extracts decrease total and LDL cholesterol (LDL-C) and 
increase HDL-C cholesterol (HDL) in animal models [1], as well as reduce the susceptibility 
to in vitro LDL oxidation [2]. Plant extracts, such as those from red yeast rice, sugar cane-
derived policosanols, and artichoke leaf, have also been shown to have a LDL-C lowering 
effect in subjects with moderate hyperlipidemia [3]. Cocoa flavonols increase the HDL-C in 
human studies [4,5]. Data from the NHANES study showed that urinary enterolignan 
concentrations were positively associated with serum HDL-C and negatively associated with 
serum triglycerides (TG) in U.S. adults [6]. In the EUROLIVE (The effect of olive oil on 
oxidative damage on European populations) study, sustained consumption of polyphenol-
rich olive oils have been shown to: 1) increase HDL-C; 2) reduce total cholesterol (TC)/
HDL-C and LDL-C/HDL-C ratios; 3) decrease in vivo lipid oxidative markers, such as 
oxidized LDL [7,8]; and 4) increase HDL cholesterol efflux from macrophages [9]. 
Supporting these data, a functional olive oil enriched with its polyphenols has also been 
shown to increase the expression of cholesterol-efflux-related genes [10].
A relatively new approach for the measurement of lipoproteins is to use nuclear magnetic 
resonance (NMR), which provide not only total particle counts of the major lipoprotein 
fractions but also their mean size and size subclass distribution [11]. In several studies the 
measurement of LDL particles (LDL-P) by NMR was more effective than those of the 
cholesterol content of the LDL, or apolipoprotein (Apo) B100 concentrations, as a positive 
risk marker for CHD [12]. Results from large studies such as MESA (Multi-Ethnic Study of 
Atherosclerosis) [13], JUPITER [14], and HPS (Heart Protection Study) [15], also showed 
that measurement of HDL particles (HDL-P) appeared to be better than HDL-C as 
cardiovascular disease risk marker. Also within the MESA study, the LDL-P/HDL-P ratio 
was shown to be an independent risk factor for CHD [16].Recently, it has been described 
that cholesterol-overloaded particles, reflected in the HDL-C/HDL-P ratio, are 
independently associated with the progression of carotid atherosclerosis in a cardiovascular-
disease-free population [17].
The aim of this work was to assess the effect of two functional olive oils, one enriched with 
its polyphenols, and the other with them and those of thyme, on the NMR lipoprotein 
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particle profile and atherogenic ratios. We hypothesized that besides its positive effect on the 
standard lipid profile, the consumption of a polyphenol-rich olive oil rich diet may also 
improve cardiovascular risk parameters, as determined by NMR, and that this may provide 
an alternative way to monitor such treatment.
 2. Materials and Methods
 2.1 Olive oil characteristics
A natural virgin olive oil (VOO, 80 ppm of phenolic compounds (PC)) was used as a control 
condition, and as a matrix to prepare a functional VOO (FVOO; PC= 500 ppm) by 
enrichment of the VOO with its own PC. A second functional olive oil was prepared by 
enrichment of the VOO both with its PC and those of thyme (FVOOT; PC=500ppm (250 
ppm from VOO and 250 ppm from thyme)). Olive oils did not differ in fat and micronutrient 
composition, with the exception of the phenolic content (Supporting Information Table S1).
 2.2 Study subjects
Hypercholesterolemic (TC >200 mg/dL) individuals were recruited from newspaper and 
university advertisements. Volunteers were preselected when their clinical record, physical 
examination, and blood pressure were within a predefined normal range and the candidate 
was non-smoker. Next, complete blood count, routine biochemical laboratory analyses, and 
urinary dipstick tests were performed. We included candidates with values, other than total 
and LDL-C, within the reference range for routine haematological and biochemical analyses. 
Exclusion criteria were the following: LDL-C ≥190 mg/dL, TG≥350 mg/dL, fasting blood 
glucose >126 mg/dL, plasma creatinine levels >1.4 mg/dL for women and >1.5 mg/dL for 
men, body mass index (BMI)>35, smokers (>1cigarrete/day), athletes with physical activity 
(>3000 METS.min/day), hypertension, multiple allergies, intestinal diseases, chronic 
diseases (i.e diabetes, cardiovascular, etc.), or other conditions that would impair the 
adherence to the study. All participants provided written informed consent, and the 
institutional ethic committee (CEIC-IMAS 2009/3347/I) approved the protocol.
 2.3. Design and study procedure
This work was conducted in the frame of the VOHF (Virgin Olive Oil and HDL 
Functionality) Study. The trial was a randomized, crossover, double-blind, controlled study. 
We randomly assigned participants consecutively to 1 of 3 sequences of raw olive oil 
administration. Participants received a daily dose of 25 mL (22 g) of raw VOO, FVOO, or 
FVOOT. Administration sequences were: FVOO,FVOOT,VOO (sequence 1, n=11); 
FVOOT,VOO,FVOO (sequence 2, n=11); and VOO,FVOO,FVOOT (sequence 3, n=11). 
Random allocation to each sequence was performed using a specific software developed at 
the Institut Hospital del Mar d’Investigacions Mèdiques (IMIM). Three-week interventions 
were preceded by 2-week washout periods, in which participants consumed a common olive 
oil, a mixture of VOO and refined olive oil, with a very low phenolic content, and avoided 
other types of raw fats as well as olive tables consumption. We chose the 2-week washout 
period to reach equilibrium in the plasma lipid profile, because longer intervention periods 
with fat-rich diets did not modify the lipid concentrations [18]. Daily doses of 25 mL of 
olive oil were blindly prepared in containers and delivered to the participants at the 
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beginning of each intervention period. Containers were assigned a code number concealed 
from participants and investigators, and disclosed only after statistical analyses completion. 
We instructed participants to return the 21 containers at the end of each intervention period 
so that the daily amount of unconsumed olive oil could be registered. 24h-urine and blood 
samples were collected at a fasting state at the start of the study and before and after each 
treatment. Plasma EDTA and serum samples were obtained by whole blood centrifugation 
and preserved at −80°C. The present clinical trial was conducted in accordance with the 
Helsinki Declaration and the Good Clinical Practice for Trials on Medical Products in the 
European Community (http://ec.europa.eu/health/files/eudralex/vol-10/3cc1aen_en.pdf). The 
protocol is registered with the International Standard Randomized Controlled Trial register 
(www.controlled-trials.com:ISRCTN77500181).
 2.4 Dietary adherence
We measured 24h-urinary hydroxytyrosol-sulfate and thymol-sulfate, before and after each 
intervention period as biomarkers of adherence to the FVOO and FVOOT interventions, 
respectively. Measurements were performed by HPLC-ESI-MS/MS [19]. A 3-day dietary 
record was administered by the participants at baseline and before and after each 
intervention-period. Participants were asked to avoid a high intake of foods rich in 
antioxidants (i.e. vegetables, legumes, fruits, etc.). A nutritionist personally advised 
participants to replace all types of habitually consumed raw fats with the olive oils catered, 
and to limit their rich-polyphenol food consumption.
 2.5. Outcomes and data collection
Main outcome measures were changes in lipoprotein particle atherogenic ratios and 
subclasses. We assessed outcome measures at the beginning of the study (baseline) and 
before (pre-intervention) and after (post-intervention) each olive oil intervention period. 
Anthropometric variables were also recorded. Blood pressure was measured with a mercury 
sphygmomanometer after at least a 10-minute rest in the seated position. Physical activity 
was recorded at baseline and at the end of the study and assessed by the MLTPAQ, which 
has been validated for its use in Spanish men and women [20, 21]. Plasma glucose, TC, and 
TG were measured using standard enzymatic automated methods and ApoAI and ApoB100 
by immunoturbidimetry, in a PENTRA-400 autoanalyzer (ABX-Horiba Diagnostics, 
Montpellier, France). HDL-C was measured by an accelerator selective detergent method 
(ABX-Horiba Diagnostics, Montpellier, France). LDL-C was calculated by the Friedewald 
equation.
Serum samples were shipped to the National Heart, Lung and Blood Institute, National 
Institutes of Health (NIH; Bethesda, MD, USA). Lipoprotein subclasses measurement was 
performed by NMR in a Vantera clinical spectrometer, produced by LipoScience (Raleigh, 
NC, U.S.A.). The NMR LipoProfile test by LipoScience involves measurement of the 
400MHz proton NMR spectrum of samples and uses the characteristic signal amplitude of 
the lipid methyl group broadcast by every lipoprotein subfraction as the basis for 
quantification. NMR using the LipoProfile-3 algorithm was performed to quantify the 
average particle size and concentrations of VLDL, LDL, and HDL. Subparticle 
concentrations were determined for 3 VLDL subclasses (large or chylomicrons: >60nm; 
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medium: 35–60nm; and small: 27–35nm); 3 LDL subclasses (intermediate-density 
lipoprotein (IDL): 23–27nm; large: 21.2–23nm; and small: 18–21.2nm); and 3 HDL 
subclasses (large: 8.8–13nm; medium: 8.2–8.8nm; and small: 7.3–8.2nm) [22]. LP-IR, a 
lipoprotein particle-derived measure of insulin resistance [23] was also assessed.
 2.6. Sample size and power analysis
Assuming a dropout rate of 15% and a Type I error of 0.05 (2-sided), a sample size of 32 
individuals allows at least 80% power to detect a statistically significant difference among 
groups of 1.5 µmol/L in the total HDL particle number. The population standard deviation of 
this variable is 4.4µmol/L [17].
 2.7. Statistical Analyses
The normality of variables was assessed by the Kolmogorov-Smirnov test. We used the 
Kruskal-Wallis test or 1-factor analysis of variance (ANOVA), as appropriate, with 
Bonferroni correction for multiple comparisons, to determine differences in baseline 
characteristics. Carryover effect was discarded by testing a period-by-treatment interaction 
term in general linear models. Comparisons among changes were carried out by a covariance 
model. Age, gender, sequence of olive oil administration, LDL-C, and baseline values were 
the covariates. The P value for a trend among oils: from VOO to FVOO to FVOOT was 
assessed. Statistical significance was defined as a P value less than 0.050 for a 2-sided test. 
We performed analyses by using SPSS for Windows, version 22 (IBM corp., Armonk, NY, 
USA).
 3. Results
 3.1 Characteristics of the study participants
From 62 subjects who were assessed for eligibility, 29 were excluded. Finally, 33 eligible 
participants (19 men, 14 women) entered the study. One participant in each sequence 
discontinued the intervention (Fig.1). We could not identify any adverse effects related to the 
olive oils intake. No significant differences in participants’ baseline characteristics were 
observed among sequences of olive oil administration, with exception of the small HDL 
particles (s-HDL) which were slightly higher in sequence 3 versus 1 (Table 1). No changes 
in daily energy expenditure in leisure-time physical activity were observed from the 
beginning to the end of the study (data not shown).
 3.2 Dietary intake and adherence
Table 2 shows the daily dietary intake after intervention periods. Diet was similar in all 
intervention groups. Participant adherence was good, as reflected in the changes in urinary 
hydroxytyrosol sulfate and thymol sulfate excretion after olive oil interventions (Fig.2). 
Hydroxytyrosol sulfate increased after FVOO (P<0.05). Thymol sulfate increased after 
FVOOT, the change reaching significance versus those of the other two olive oils (P<0.05).
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 3.3 Classical cardiovascular risk factors
Functional olive oils consumption did not change either glucose levels or the classical 
cardiovascular lipid profile (TC, TG, LDL-C and HDL-C), nor ApoAI or ApoB100 
concentrations versus VOO. An exception was a decrease in LDL-C after FVOO, which was 
significant versus changes after the other two olive oil interventions (P<0.05) (Table 3). No 
changes were observed in blood pressure or BMI associated with the interventions.
 3.4. NMR lipoprotein particle counts and subclasses
Total LDL-P, IDL-P and total ApoB100 containing lipoproteins concentrations decreased 
after FVOO, the decrease reaching significance versus changes after VOO and FVOOT 
(P<0.001). The decrease observed in small LDL particles after FVOO intervention was 
statistically significant (P<0.05) when compared with the changes observed after FVOOT 
intervention. LDL particle size decreased after FVOO intervention, the decrease reaching 
significance versus changes after the other interventions (P<0.05) (Table 3).
Comparison among changes after interventions in HDL-related measures (Table 3) showed 
that both FVOO and FVOOT promoted an increase in large HDL (I-HDL) particles versus 
VOO (P<0.05). s-HDL particles decreased after FVOO intervention versus changes after 
VOO and FVOOT (P<0.05). Both functional olive oils increased HDL particle size when 
comparing with changes after the VOO intervention, the increase being higher after FVOO 
(P<0.05). Both functional olive oils decreased medium VLDL particles versus VOO 
intervention, the decrease being higher after FVOO (P<0.05). The average VLDL particle 
size decreased after FVOO intervention, reaching significance versus changes observed after 
the other two olive oil interventions (P<0.05).
 3.5. Atherogenic lipoprotein particle ratios and LP-IR
Figure 3 shows the results obtained in the atherogenic lipoprotein particle ratios and LP-IR 
after FVOO and FVOOT versus control (VOO). The LDL-P/HDL-P ratio decreased after 
FVOO (P<0.05) versus VOO and FVOOT (P<0.05). Both functional olive oils also 
decreased the HDL-C/HDL-P and the s-HDL/1-HDL ratios (P<0.05). The decrease in s-
HDL/l-HDL after FVOO was higher than that after FVOOT (P<0.05). The LP-IR ratio also 
decreased after both functional olive oils (P<0.05).
 4. Discussion
In this study, we assessed the effects of polyphenol-rich olive oils on lipoprotein particle 
atherogenic ratios and subclasses distribution, as determined by NMR. From our results, 
polyphenols from olive oil decreased LDL-C and the LDL-P/HDL-P ratio, and improved the 
lipoprotein subclasses by decreasing total ApoB100 containing lipoproteins, LDL and IDL 
particle concentration, as well as LDL and VLDL particle size. Both, polyphenols from olive 
oil, and combined equally with those of thyme, decreased medium VLDL particles, 
increased large HDL particles, decreased s-HDL/l-HDL and HDL-C/HDL-P ratios, and the 
lipoprotein insulin resistance index (LP-IR) (P<0.05).
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LDL-C, LDL-P, LDL size, and the LDL-P/HDL-P ratio have all been shown to be directly 
associated with the risk of coronary heart disease (CHD) [24, 25]. In the present work, olive 
oil polyphenols decreased all these cardiovascular risk biomarkers. The decrease in LDL-C 
observed is in agreement with that recently reported at postprandial state after extra-VOO 
consumption [26]. Polyphenols from green tea and from herbs have shown to have 
hypocholesterolemic effects lowering LDL-C in human [27] and animal models [28]. 
Mechanisms for explaining this effect are still unknown. The decrease in LDL-P after 
polyphenol-rich olive oil consumption observed in this study is also in agreement with our 
recent results from the EUROLIVE study with rich-polyphenol olive oil [29]. Concerning 
the decrease in LDL size, depletion of cholesteryl esters and triglyceride enrichment of LDL 
particles are associated with a decreased size, as well as an increased density of these 
particles, and these properties reduce their affinity for the LDL receptor [30]. As a 
consequence, small and dense LDL are likely to have an increased residence time in the 
circulation, making them more susceptible to oxidation or glycosylation, which considerably 
increases their atherogenic potential [31]. Olive oil polyphenols have shown to protect 
human LDL in vivo from oxidation [7]. In this sense, on November 2011, the European 
Food Safety Authority (EFSA) released a claim concerning the benefits of polyphenol-rich 
olive oil consumption protecting the LDL from oxidation [32]. Of all LDL particle 
biomarkers tested, the ratio LDL-P/HDL-P seems to have the strongest independent 
association with CHD, with significant net reclassification improvements in the AHA/ACC 
CHD risk scores [16].
To date the strong epidemiological association between HDL-C and CHD has failed to be 
translated into clinical benefit in terms of drug development. HDL, however, encompasses a 
heterogeneous population of lipoproteins that differ in shape, density, size, surface charge, 
and antigenicity that could exhibit differences in functionality irrespective of its cholesterol 
content. Studies reporting associations between HDL particle subclasses and CHD have 
been conflicting, and it is still unclear whether specific subclasses of HDL are more 
cardioprotective [33]. In most, but not all population studies [34], small HDL particles are 
considered to be more strongly associated with increased CHD risk than large HDL [35, 36]. 
High levels of small HDL particles and/or low levels of the large HDL ones are often present 
in CHD, ischemic stroke, and type-II diabetes mellitus [37–39]. In our study we observed a 
decrease in the s-HDL/l-HDL ratio after both functional olive oils consumption. Our results 
agree with those previously obtained in the VOHF study, when, by using gradient 
electrophoresis, an increase in the large less dense HDL (HDL2) and a decrease in the small 
denser HDL (HDL3) after both functional olive oils was observed, although significance was 
only reached for FVOOT [40]. Differences among results could be explained by the fact that 
different methods (NMR versus gradient electrophoresis) and scores for HDL subclasses 
classification were used.
A potentially important advance in cardiovascular biomarker testing related to HDL is the 
HDL-C/HDL-P ratio and is considered to be a potential new measure of HDL 
cardioprotective function [17, 41]. This ratio indicates the enrichment of the HDL particle in 
cholesterol, and has been shown to be directly related with the atherosclerosis progression in 
cardiovascular-free individuals [17]. In our study, both functional olive oils decreased the 
HDL-C/HDL-P ratio versus a natural VOO. Thus, olive oil rich in its polyphenols and those 
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from thyme were able to decrease the cholesterol enrichment of HDL. The most likely 
mechanism proposed to explain the benefits of this decrease is that cholesterol enrichment of 
HDL impairs its ability to promote the efflux of cholesterol from peripheral cells, considered 
to be one of the main HDL anti-atherogenic functions and inversely related to CVD risk. 
This cholesterol efflux impairment can be explained by the fact that these cholesterol-
overloaded HDLs may act as donor more than as acceptors of cholesterol from peripheral 
tissues [42]. Moreover, HDL particles enriched in cholesterol may be less prone to be 
recognized by hepatic SR-BI receptors and thus, cholesterol clearance may be compromised. 
This fact can be explained by the assertion that myeloperoxidase enzyme oxidizes 
phospholipids and ApoA1 present in large, dense HDL [43]. Moreover, as reviewed by Lee 
et al., SR-BI have a lower binding affinity for oxidized phospholipids, blocking thus 
cholesteryl esters transfer from oxidized HDLs to hepatic cells [44]. In addition, cholesterol-
enriched HDLs become more pro-inflammatory, as well as more prone to be oxidised, which 
in turn impairs cholesterol efflux [17, 42].. In agreement with the results obtained in the 
present study, we also previously reported that olive oil polyphenols increase the efflux of 
cholesterol in vivo in humans [9], at least in part due via a transcriptomic effect [10]. 
Consumption of olive oils rich in polyphenols promoted a greater HDL stability, reflected in 
a triglyceride-poor core, and decreased the HDL oxidative status, through an increase in the 
olive oil polyphenol metabolites content in the lipoprotein [9].
Dyslipidemia among individuals with type 2 diabetes is characterized not only by high TG 
concentrations and low HDL-C concentrations, but also by decreases in the size of LDL and 
HDL particles and increases in the size of VLDL particles [45].In individuals with insulin 
resistance (IR) and diabetes, VLDL particle size is inversely associated with the glucose 
disposal rate (GRD) [46] the gold standard for assessing insulin sensitivity, and directly 
associated with incident hypertension [46]. In our study, FVOO consumption reduced the 
VLDL particle size in dyslypemic individuals versus the other olive oils, and both functional 
olive oils were effective, versus VOO, on reducing medium VLDL subclass concentration. 
Larger VLDL particles have been associated with diabetes [45], and both large and medium 
VLDL concentrations with hypertension [46]. The American College of Endocrinology Task 
Force on the IR Syndrome states the clinical preventive value of identifying individuals with 
IR [47]. One measure to assess IR is the LP-IR index derived from lipoprotein NMR 
measurements. LP-IR is directly related with the HOMA index and inversely related with 
GRD, and has been proposed as a simple method for assessing the risk to develop a 
prediabetic or diabetic state [23].In agreement with all the other benefits derived from the 
consumption of the functional olive oils on the lipoprotein subclasses, both FVOO and 
FVOOT also decreased the LP-IR index in our dyslypemic individuals.
In summary, sustained consumption of VOO enriched with its PC (FVOO), or equally 
enriched with them and those of thyme (FVOOT), promoted benefits, particularly FVOO, on 
lipoprotein subclasses distribution versus a natural virgin olive oil (VOO). Compared with 
VOO consumption, both functional olive oils decreased the LP-IR index and the atherogenic 
ratios: HDL-C/HDL-P ands-HDL/l-HDL. FVOO also improved the LDL-P/HDL-P ratio. To 
the best of our knowledge this is the first time that a decrease in these atherogenic ratios 
associated to a dietary intervention has been reported. Our results provide first level 
evidence of the benefits of olive oil polyphenols and those from thyme on lipoprotein 
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subclasses distribution and their associated ratios. Olive oil, a recognized healthy food, can 
not, however, be readily consumed in large quantities. Thus, polyphenol-enriched olive oil is 
a way of increasing its healthy properties while the same amount of fat is consumed. Data 
from this study provide further evidence to recommend polyphenol-rich olive oil 
consumption as a possibly useful and complementary tool for the management of 
cardiovascular risk individuals.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
 Acknowledgments
This study was supported by the Spanish Ministry of Education and Science, The VOHF Project 
(AGL2009-13517). Work done by ATR was supported by the intramural National Heart, Lung and Blood Institute 
of the National Institutes of Health, in Bethesda, MD. We thank NUPROAS HB for their substantial contribution 
interpreting the data and revising the manuscript critically.
 Abbreviations and Acronyms
CHD coronary heart disease
HDL-C high density lipoprotein cholesterol
HPLC-ESI-MS/MS high performance liquid chromatography-electrospray 
tandem mass spectrometry
JUPITER Justification for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin
LDL-C low-density lipoprotein cholesterol
LP-IR Lipoprotein Insulin Resistance Index
MLTPAQ Minnesota Leisure Time Physical Activity Questionnaire
NHANES National Health and Nutrition Examination Survey
References
1. Alamgeer, Akhtar M-S, Jabeen Q, Khan H-U, Maheen S, et al. Pharmacological evaluation of 
antihypertensive effect of aerial parts of Thymus linearis benth. Acta Pol. Pharm. 2014; 71:677–
682. [PubMed: 25272894] 
2. Kulisić T, Krisko A, Dragović-Uzelac V, Milos M, Pifat G. The effects of essential oils and aqueous 
tea infusions of oregano (Origanum vulgare L. spp. hirtum), thyme (Thymus vulgaris L.) and wild 
thyme (Thymus serpyllum L.) on the copper-induced oxidation of human low-density lipoproteins. 
Int. J. Food Sci. Nutr. 2007; 58:87–93. [PubMed: 17469764] 
3. Ogier N, Amiot M-J, Georgé S, Maillot M, Mallmann C, et al. LDL-cholesterol-lowering effect of a 
dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur. J. Nutr. 
2013; 52:547–557. [PubMed: 22527287] 
4. Mursu J, Voutilainen S, Nurmi T, Rissanen T-H, Virtanen J-K, et al. Dark chocolate consumption 
increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in 
healthy humans. Free Radic. Biol. Med. 2004; 37:1351–1359. [PubMed: 15454274] 
Fernández-Castillejo et al. Page 9
Mol Nutr Food Res. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5. Sarriá B, Martínez-López S, Sierra-Cinos J-L, García-Diz L, Goya L, et al. Effects of bioactive 
constituents in functional cocoa products on cardiovascular health in humans. Food Chem. 2015; 
174:214–218. [PubMed: 25529672] 
6. Peñalvo J-L, López-Romero P. Urinary enterolignan concentrations are positively associated with 
serum HDL cholesterol and negatively associated with serum triglycerides in U.S. adults. J. Nutr. 
2012; 142:751–756. [PubMed: 22378329] 
7. Covas M-I, Nyyssönen K, Poulsen H-E, Kaikonnen J, Zunft H-J, et al. The effect of polyphenols in 
olive oil on heart disease risk factors. Ann. Intern. Med. 2006; 145:333–341. [PubMed: 16954359] 
8. Gómez M, Vila J, Elosua R, Molina L, Bruguera J, et al. Relationship of lipid oxidation with 
subclinical atherosclerosis and 10-year coronary events in general population. Atherosclerosis. 
2014; 232:134–140. [PubMed: 24401227] 
9. Hernáez A, Fernández-Castillero S, Farràs M, Catalán U, Subirana I, et al. Olive oil polyphenols 
enhance high density lipoprotein function in humans. A randomized controlled trial. Arterioscler. 
Thromb. Vasc. Biol. 2014; 34:2115–2119. [PubMed: 25060792] 
10. Farràs M, Valls R-M, Fernández-Castillejo S, Giralt M, Solà R, et al. Olive oil polyphenols 
enhance the expression of cholesterol efflux related genes in vivo in humans. A randomized 
controlled trial. J. Nutr. Biochem. 2013; 24:1334–1339. [PubMed: 23333095] 
11. Otvos J-D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance 
spectroscopy. Clin. Lab. 2002; 48:171–180. [PubMed: 11934219] 
12. Cole T-G, Contois J-H, Csako G, McConnell J-P, Remaley AT, et al. Association of apolipoprotein 
B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 
clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working 
Group on Best Practices. Clin. Chem. 2013; 59:752–770. [PubMed: 23386699] 
13. Mackey R-H, Greenland P, Goff D-C Jr, Lloyd-Jones D, Sibley C-T, et al. High-density lipoprotein 
cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA 
(Multi-Ethnic Study of Atherosclerosis. J. Am. Coll. Cardiol. 2012; 60:508–516. [PubMed: 
22796256] 
14. Mora S, Glynn R-J, Ridker P-M. High-density lipoprotein cholesterol, size, particle number, and 
residual vascular risk after potent statin therapy. Circulation. 2013; 128:1189–1197. [PubMed: 
24002795] 
15. Parish S, Offer A, Clarke R, Hopewell J-C, Hill M-R, et al. Lipids and lipoproteins and risk of 
different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012; 125:2469–
2478. [PubMed: 22539783] 
16. Steffen B-T, Guan W, Remaley A-T, Paramsothy P, Heckbert S-R, et al. Use of lipoprotein particle 
measures for assessing coronary heart disease risk Post-American Heart Association/American 
Collegue of Cardiology guidelines. Arterioscler. Thromb. Vasc. Biol. 2015; 35:448–454. [PubMed: 
25477346] 
17. Qi Y, Fan J, Liu J, Wang W, Wang M, et al. Cholesterol-overloaded HDL particles are 
independently associated with progression of carotid atherosclerosis in a cardiovascular disease-
free population. J. Am. Coll. Cardiol. 2015; 65:355–363. [PubMed: 25634834] 
18. Fielding C-J, Havel R-J, Todd K-M, Yeo K-E, Schloetter M-C, et al. Effects of dietary cholesterol 
and fat saturation on plasma lipoproteins in an ethnically diverse population of healthy young men. 
J. Clin. Invest. 1995; 95:611–618. [PubMed: 7860745] 
19. Rubió L, Farrás M, de la Torre R, Maciá A, et al. Metabolite profiling of olive oil and thyme 
phenols after a sustained intake of two phenol-enriched olive oils by humans: Identification of 
compliance markers. Food Res. Int. 2014; 65:59–68.
20. Elosua R, Marrugat J, Molina L, Pons S, Pujol E. Validation of the Minnesota Leisure Time 
Physical Activity Questionnaire in Spanish men. The MARATHOM Investigators. Am. J. 
Epidemiol. 1994; 139:1197–1209. [PubMed: 8209878] 
21. Elosua R, García M, Aguilar A, Molina L, Cobas M-I, et al. Validation of the Minnesota Leisure 
Time Physical Activity Questionnaire In Spanish Women. Med. Sci. Sports Exerc. 2000; 32:1431–
1437. [PubMed: 10949009] 
22. Jeyarajah E-J, Cromwell W-C, Otvos J-D. Lipoprotein particle analysis by nuclear magnetic 
resonance spectroscopy. Clin. Lab. Med. 2006; 26:847–870. [PubMed: 17110242] 
Fernández-Castillejo et al. Page 10
Mol Nutr Food Res. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
23. Shalaurova I, Connelly M-A, Garvey W-T, Otvos J-D. Lipoprotein Insulin Resistance Index: A 
Lipoprotein Particle–Derived Measure of Insulin Resistance. Metab. Syndr. Relat. Disord. 2014; 
12:422–429. [PubMed: 24959989] 
24. Blake G-J, Otvos J-D, Rifai N, Ridker P-M. Low-density lipoprotein particle concentration and 
size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular 
disease in women. Circulation. 2002; 106:1930–1937. [PubMed: 12370215] 
25. El Harchaoui K, van der Steeg W-A, Stroes E-S, Kuivenhoven J-A, et al. Value of low-density 
lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy 
men and women: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 2007; 
49:547–553. [PubMed: 17276177] 
26. Violi F, Loffredo L, Pignatelli P, Angelico F, Barimoccia S, et al. Extra virgin olive oil use is 
associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects. 
Nutr. Diabetes. 2015; 5:e172. [PubMed: 26192450] 
27. Larsson S-C. Coffee, tea, cocoa and risk of stroke. Stroke. 2014; 45:309–314. [PubMed: 
24326448] 
28. Bravo L, Mateos R, Sarriá B, Baeza G, Lecumberri E, et al. Hypocholesterolaemic and antioxidant 
effects of yerba mate (Ilex paraguariensis) in high-cholesterol fed rats. Fitoterapia. 2014; 92:219–
229. [PubMed: 24291756] 
29. Hernáez A, Remaley A-T, Farràs M, Fernández-Castillejo S, Subirana I, et al. Olive oil 
polyphenols decrease LDL concentrations and LDL atherogenicity in men in a randomized 
controlled trial. J. Nutr. 2015; 145:1692–1697. [PubMed: 26136585] 
30. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, et al. On the pathogenesis of 
atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic 
moiety. J. Exp. Med. 1995; 182:1959–1971. [PubMed: 7500042] 
31. Lyons T-J. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am. J. Cardiol. 
1993; 71:26B–31B.
32. EFSA Panel on Dietetic Products. Nutrition and allergies (NDA). Scientific opinion on the 
substantiation of health claims related to polyphenols in olive oil and protection of LDL particles 
from oxidative damage. EFSA Journal. 2011; 9:2033. [accessed on September,2015] Available 
from: http://www.efsa.europa.eu/en/efsajournal/pub/2033.htm. 
33. Akinkuolie A-O, Paynter N-P, Padmanabhan L, Mora S. High density lipoprotein subclass 
heterogeneity and incident coronary heart disease. Circ. Cardiovasc. Qual. Outcomes. 2014; 7:55–
63. [PubMed: 24248942] 
34. Otvos J-D, Collins D, Freedman D-S, Shalaurova I, Schaefer E-J, et al. Low-density lipoprotein 
and high-density lipoprotein particle subclasses predict coronary events and are favourably 
changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention 
Trial. Circulation. 2006; 113:1556–1563. [PubMed: 16534013] 
35. Martin S-S, Khokhar A-A, May H-T, Kulkarni K-R, Blaha M-K, et al. HDL cholesterol subclasses, 
myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators 
collaborative. Eur. Heart J. 2015; 36:22–30. [PubMed: 24980493] 
36. Joshi P-H, Toth P-P, Lirette S-T, Griswold M-E, Massaro J-M, et al. Association of high-density 
lipoprotein subclasses and incident coronary heart disease: the Jackson Heart and Framingham 
Offspring Cohort Studies. Eur. J. Prev. Cardiol. 2016; 23:41–49. [PubMed: 25062744] 
37. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, Jelic-Ivanovic Z, Bogavac-Stanojevic N, et al. 
LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. 
Atherosclerosis. 2010; 210:548–554. [PubMed: 20022325] 
38. Borggreve S-E, De Vries R, Dullaart R-P-F. Alterations in high-density lipoprotein metabolism and 
reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic 
enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur. J. Clin. Invest. 2003; 
33:1051–1069. [PubMed: 14636288] 
39. Sankaranarayanan S, Oram J-F, Asztalos B-F, Vaughan A-M, Lund-Katz S, et al. Effects of 
acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J. Lipid 
Res. 2009; 50:275–284. [PubMed: 18827283] 
Fernández-Castillejo et al. Page 11
Mol Nutr Food Res. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
40. Farràs M, Castañer O, Martin-Pelaez S, Hernáez A, Schröder H, et al. Complementary phenol-
enriched olive oil improves HDL characteristics in hypercholesterolemic subjects. A randomized, 
double-blind, crossover, controlled trial. The VOHF study. Mol. Nutr. Food Res. 2015; 59:1758–
1770. [PubMed: 26011257] 
41. Remaley A-T. HDL cholesterol/HDL particle ratio. A new measure for HDL function? J. Am. Coll. 
Cardiol. 2015; 65:364–366. [PubMed: 25634835] 
42. Khera A-V, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke M-F, et al. Cholesterol efflux 
capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011; 364:127–
135. [PubMed: 21226578] 
43. Huang Y, Didonato J-A, Levison B-S, Schmitt D, Li L, et al. An abundant dysfunctional 
apolipoprotein A1 in human atheroma. Nat med. 2014; 20(2):193–203. [PubMed: 24464187] 
44. Lee S, Birukov K-G, Romanoski C-E, Springstead J-R, Lusis A-J, et al. Role of phospholipid 
oxidation products in atherosclerosis. Circ Res. 2012; 111(6):778–799. [PubMed: 22935534] 
45. Garvey W-T, Kwon S, Zheng D, Shaughnessy S, Wallace P, et al. Effects of insulin resistance and 
type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear 
magnetic resonance. Diabetes. 2003; 52:453–462. [PubMed: 12540621] 
46. Paynter N-P, Sesso H-D, Conen D, Otvos J-D, Mora S. Lipoprotein subclass abnormalities and 
incident hypertension in initially healthy women. Clin. Chem. 2011; 57:1178–1187. [PubMed: 
21700954] 
47. Einhorn D, Reaven G-M, Cobin R-H, Ford E, Ganda O-P, et al. American College of 
Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 2003; 9:237–
252. [PubMed: 12924350] 
Fernández-Castillejo et al. Page 12
Mol Nutr Food Res. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Flow-chart of the study
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Figure 2. 
Changes in urinary hydroxytyrosol sulfate and thymol sulfate after olive oil interventions. 
VOO, virgin olive oil; FVOO, functional virgin olive oil enriched with its phenolic 
compounds (500 ppm); FVOOT, functional olive enriched with its phenolic compounds (250 
ppm) and those from thyme (250 ppm). *P < 0.05 versus VOO; † P< 0.001 versus FVOO.
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Figure 3. 
Changes (mean ± S.E.M) in atherogenic lipoprotein particle atherogenic ratios ratios and 
lipoprotein insulin resistance index (LP-IR) after consumption of functional olive oils versus 
natural virgin olive oil (VOO). FVOO, functional virgin olive oil enriched with its phenolic 
compounds (500 ppm); FVOOT, functional olive enriched with its phenolic compounds (250 
ppm) and those from thyme (250 ppm). LDL-P, low density lipoprotein particle-
concentration; HDL-P, high density lipoprotein particle-concentration; HDL-C, HDL 
cholesterol; s-HDL, small HDL lipoprotein particle concentration; l-HDL, large HDL 
lipoprotein particle concentration. *P<0.001 versus VOO. Differences between functional 
olive oils are indicated by square brackets with the corresponding significance.
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Table 1
Baseline characteristics of the study participants.
Variable Sequence 1 Sequence 2 Sequence 3
Age (y) 54.9 ± 12.6 55.3 ± 11.9 55.5 ± 7.8
Gender (male/female) 5/6 7/4 7/4
Body mass Index (kg/m2) 25.6 ± 3.7 26.3 ±5.2 27.8 ± 4.7
Physical activity (METs.min/w) 3499
(1755–8092)
1189
(742–1687)
3322
(861–3664)
Systolic blood pressure (mmHg) 125 ± 18.7 128 ± 16.7 130 ± 17.9
Diastolic blood pressure (mmHg) 68.1 ± 13.5 72.3 ± 9.3 71.9 ± 13.4
Glucose (mg/dL) 88.5 ± 11.6 93.0 ± 13.3 90.9 ± 10.5
Total cholesterol (mg/dL) 228 ± 42.7 232 ± 32.7 219 ± 31.2
LDL measures
  LDL cholesterol (mg/dL) 150 ± 32.3 152 ± 28.5 142 ± 25.7
  ApoB100 (mg/dL) 115 ± 0.21 117 ± 0.18 109 ± 0.16
  NMR LDL particle concentration (nmol/L)
    Total 1473 ± 348 1420 ± 319 1322 ± 254
    IDL 297 ± 95.1 295 ±165 289 ±79.4
    Large 593 ± 139 515 ± 152 433 ± 227
    Small 600 ± 389 560 ± 381 464 ± 199
  Average NMR LDL particle size (nm) 21.2 ± 0.69 21.1 ± 0.71 21.0 ± 0.60
VLDL measures
  Triglycerides, mg/dL 94 (75 – 149) 119 (95 – 168) 117 (81 – 126)
  NMR VLDL particle concentration (nmol/L)
    Total 54.5 ± 36.1 65.6 ± 26.6 59.4 ± 32.0
    Large 3.8 ± 4.6 5.3 ± 4.2 2.8 ± 2.1
    Medium 16.2 ± 11.5 20.2 ± 11.3 16.8 ± 10.7
    Small 35.0 ± 26.2 39.6 ± 16.5 39.5 ± 21.9
  Average NMRV VLDL particle size (nm) 45.8 ± 9.7 48.2 ± 5.5 45.3 ± 3.8
NMR ApoB100-containing particles
  concentration (nmol/L)
1517± 310 1478 ± 298 1384± 235
HDL measures
  HDL cholesterol (mg/dL) 52.8 ± 11.7 53.0 ± 12.8 53.4 ± 9.5
  ApoAI (mg/dL) 142 ± 0.23 137 ± 0.21 147 ± 0.16
  NMR HDL particle concentration (µmol/L)
    Total 35.6 ± 5.9 34.6 ± 5.3 38.0 ± 4.0
    Large 7.0 ± 3.8 6.2 ± 3.4 6.6 ± 2.6
    Medium 13.0 ± 6.2 9.2 ± 6.3 9.3 ± 4.7
    Small 14.4 ± 6.1 18.0 ± 5.2 21.1 ± 4.9*
  Average NMR HDL particle size (nm) 9.4 ± 0.63 9.3 ± 0.54 9.2 ± 0.34
Values are expressed as means ± SD or median (25th–75th percentile). Sequence 1: FVOO, FVOOT, VOO; Sequence 2: FVOOT, VOO, FVOO; 
Sequence 3: VOO, FVOO, FVOOT.
*
P<0.05 versus Sequence 1
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